UMIN ID: UMIN000056024
Registered date:14/11/2024
Pemafibrate Add-on theRapy in Type 2 diabetes with MASLD uNdErgoing SGLT2 inhibitoR-Juntendo Shizuoka:PARTNER-JS
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Type 2 diabetes dyslipidemia MASLD |
| Date of first enrollment | 2024/10/01 |
| Target sample size | 100 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | ALT |
|---|---|
| Secondary Outcome | BMI, AST, TG |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Contraindication for pemafibrate |
Related Information
| Primary Sponsor | Juntendo University |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Kowa |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Takashi Nomiyama |
| Address | 1129, Nagaoka, Izunokunishi, Shizuoka, Japan Japan 410-2295 |
| Telephone | 0559483111 |
| nomiyama@juntendo.ac.jp | |
| Affiliation | Juntendo University Shizuoka Hospital Department of Diabetes, Endocrinology and Metabolism |
| scientific contact | |
| Name | Takashi Nomiyama |
| Address | 1129, Nagaoka, Izunokunishi, Shizuoka, Japan Japan |
| Telephone | 0559483111 |
| nomiyama@juntendo.ac.jp | |
| Affiliation | Juntendo University Shizuoka Hospital Department of Diabetes, Endocrinology and Metabolism |